Published Date: 08 Mar 2023
People with hypertension (high blood pressure in the arteries that supply the lungs, also known as PAH) have up to a two-fold reduction in pulmonary vascular resistance (PVR) when taking PAH.
Read Full NewsJanelle Wagner, PhD, a clinical psychologist and research professor at the Medical University of South Carolina, provided clinical insights on a recently presented study on whether elevated ADHD symptoms impact post epilepsy surgery seizure freedom.
Here's some of what is coming soon to NeurologyLive® this week.
A new large-scale analysis revealed that patients with identical EDSS scores can exhibit distinct patterns of functional impairment, identified using artificial intelligence–based clustering algorithms.
Rheumatology in 2025: Year in Review
Early Week 2 Response Predicts Sustained Benefit with Adjunct Cariprazine in MDD
KDIGO Releases New Guideline for Anemia in Chronic Kidney Disease
Chronic Kidney Disease Paired With Social Frailty May Increase Depression Risk
1.
Ivonescimab Tops Pembrolizumab in PD-L1-Positive, Advanced NSCLC
2.
Virtual Reality Travel Reduces Cancer Pain.
3.
NEJM: Pirtobrutinib is effective in CLL patients who have received prior BTK inhibitor therapy.
4.
Even a few mutated cells can significantly impact how blood cancers develop, study finds
5.
Omitting Biopsy After Negative MRI Halves Diagnoses of Insignificant Prostate Cancer
1.
Circulating Tumor Cells & Platelet Interactions: Crosstalk for Therapeutic Advances
2.
Optimizing Oncology Practice Revenue: Billing Software, Payer Trends, and Financial Navigation Tools
3.
AI-Powered Case Studies in Oncology: Elevating Clinical Influence Through Real-World Data
4.
Everything You Need to Know About Leiomyomas: A Comprehensive Guide
5.
Seeing the Unseen: Examining Chancroid Through Images
1.
International Lung Cancer Congress®
2.
Future NRG Oncology Meeting
3.
Genito-Urinary Oncology Summit 2026
4.
ISMB 2026 (Intelligent Systems for Molecular Biology)
5.
Annual International Congress on the Future of Breast Cancer East
1.
Untangling The Best Treatment Approaches For ALK Positive Lung Cancer - Part VI
2.
Newer Immunotherapies for Myeloma- A Comprehensive Overview- Part II
3.
Guideline Recommendations of Lorlatinib as First-Line Treatment for ALK+ NSCLC
4.
Efficient Management of First line ALK-rearranged NSCLC - Part VII
5.
Molecular Contrast: EGFR Axon 19 vs. Exon 21 Mutations - Part VII
© Copyright 2025 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation